Birkelo Bethany C, Koyner Jay L, Ostermann Marlies, Bhatraju Pavan K
Division of Nephrology, Department of Medicine, University of Minnesota, Minneapolis, MN.
Section of Nephrology, Department of Medicine, University of Chicago, Chicago, IL.
Crit Care Med. 2024 Jul 1;52(7):1127-1137. doi: 10.1097/CCM.0000000000006328. Epub 2024 Jun 13.
Acute kidney injury (AKI) is a common form of organ dysfunction in the ICU. AKI is associated with adverse short- and long-term outcomes, including high mortality rates, which have not measurably improved over the past decade. This review summarizes the available literature examining the evidence of the need for precision medicine in AKI in critical illness, highlights the current evidence for heterogeneity in the field of AKI, discusses the progress made in advancing precision in AKI, and provides a roadmap for studying precision-guided care in AKI.
Medical literature regarding topics relevant to precision medicine in AKI, including AKI definitions, epidemiology, and outcomes, novel AKI biomarkers, studies of electronic health records (EHRs), clinical trial design, and observational studies of kidney biopsies in patients with AKI.
English language observational studies, randomized clinical trials, reviews, professional society recommendations, and guidelines on areas related to precision medicine in AKI.
Relevant study results, statements, and guidelines were qualitatively assessed and narratively synthesized.
We synthesized relevant study results, professional society recommendations, and guidelines in this discussion.
AKI is a syndrome that encompasses a wide range of underlying pathologies, and this heterogeneity has hindered the development of novel therapeutics for AKI. Wide-ranging efforts to improve precision in AKI have included the validation of novel biomarkers of AKI, leveraging EHRs for disease classification, and phenotyping of tubular secretory clearance. Ongoing efforts such as the Kidney Precision Medicine Project, identifying subphenotypes in AKI, and optimizing clinical trials and endpoints all have great promise in advancing precision medicine in AKI.
急性肾损伤(AKI)是重症监护病房(ICU)中常见的器官功能障碍形式。AKI与不良的短期和长期预后相关,包括高死亡率,在过去十年中死亡率并未得到显著改善。本综述总结了现有文献,这些文献探讨了危重症中AKI精准医学必要性的证据,强调了AKI领域目前存在异质性的证据,讨论了在提高AKI精准度方面取得的进展,并提供了研究AKI精准导向治疗的路线图。
关于AKI精准医学相关主题的医学文献,包括AKI定义、流行病学和预后、新型AKI生物标志物、电子健康记录(EHR)研究、临床试验设计以及AKI患者肾活检的观察性研究。
关于AKI精准医学相关领域的英文观察性研究、随机临床试验、综述、专业学会建议和指南。
对相关研究结果、陈述和指南进行定性评估并进行叙述性综合。
在本讨论中,我们综合了相关研究结果、专业学会建议和指南。
AKI是一种包含多种潜在病理状况的综合征,这种异质性阻碍了AKI新型治疗方法的开发。为提高AKI精准度所做的广泛努力包括验证AKI的新型生物标志物、利用EHR进行疾病分类以及肾小管分泌清除的表型分析。诸如肾脏精准医学项目、识别AKI的亚表型以及优化临床试验和终点等正在进行的努力,在推进AKI精准医学方面都具有巨大潜力。